Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We explored longitudinal changes associated with switching to hybrid closed-loop (HCL) insulin delivery systems in adults with type 1 diabetes and elevated HbA1c levels despite the use of intermittently scanned continuous glucose monitoring (isCGM) and insulin pump therapy. RESEARCH DESIGN AND METHODS: We undertook a pragmatic, preplanned observational study of participants included in the National Health Service England closed-loop pilot. Adults using isCGM and insulin pump across 31 diabetes centers in England with an HbA1c ≥8.5% who were willing to commence HCL therapy were included. Outcomes included change in HbA1c, sensor glucometrics, diabetes distress score, Gold score (hypoglycemia awareness), acute event rates, and user opinion of HCL. RESULTS: In total, 570 HCL users were included (median age 40 [IQR 29–50] years, 67% female, and 85% White). Mean baseline HbA1c was 9.4 ± 0.9% (78.9 ± 9.1 mmol/mol) with a median follow-up of 5.1 (IQR 3.9–6.6) months. Of 520 users continuing HCL at follow-up, mean adjusted HbA1c reduced by 1.7% (95% CI 1.5, 1.8; P < 0.0001) (18.1 mmol/mol [95% CI 16.6, 19.6]; P < 0.0001). Time in range (70–180 mg/dL) increased from 34.2 to 61.9% (P < 0.001). Individuals with HbA1c of ≤58 mmol/mol rose from 0 to 39.4% (P < 0.0001), and those achieving ≥70% glucose time in range and <4% time below range increased from 0.8 to 28.2% (P < 0.0001). Almost all participants rated HCL therapy as having a positive impact on quality of life (94.7% [540 of 570]). CONCLUSIONS: Use of HCL is associated with improvements in HbA1c, time in range, hypoglycemia, and diabetes-related distress and quality of life in people with type 1 diabetes in the real world.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“over 14 days per the international consensus guidelines and in keeping with routine clinical practice (20).”
Gregory, G. A., Robinson, T. I. G., Linklater, S. E., Wang, F., Colagiuri, S., de Beaufort, C., Donaghue, K. C., Harding, J. L., Wander, P. L., Zhang, X., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00218-2 · Cited by 1,149
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Development of a brief diabetes distress screening instrument
Fisher, L., Glasgow, R. E., Mullan, J. T., Skaff, M. M., & Polonsky, W. H. (2008) · The Annals of Family Medicine · doi:10.1370/afm.842 · Cited by 474 · cited 1×
“Secondary outcomes included CGM metrics time in range (TIR) (70–180mg/dL), time below range (TBR) (<70 mg/dL), glucose management indicator (GMI) (estimated HbA1c), Diabetes Distress Scale 2 (DDS2) score (18), Gold score (19), event rates, weight, BMI, and user opinion of HCL (using a 7-point Likert scale where 1 = st…”
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440 · cited 1×
“The findings observed are less generalizable to individuals with lower baseline HbA1c levels, though HCL use is supported in these individuals by existing randomized controlled trial evidence (8,9,11).”
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Self-citationBergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250 · cited 1×
“Additionally, these studies often lacked data on HbA 1c (instead reporting sensor-derived glucose data) and hospital admissions (13 – 16).”
Carlson, A. L., Sherr, J. L., Shulman, D. I., Garg, S. K., Pop-Busui, R., Bode, B. W., Lilenquist, D. R., Brazg, R. L., Kaiserman, K. B., Kipnes, M. S., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0319 · Cited by 230
Multicenter, randomized trial of a bionic pancreas in type 1 diabetes
Bionic Pancreas Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2205225 · Cited by 216
Cited by
Hyperglycemic crises in adults with diabetes: a consensus report
Umpierrez, G. E., Davis, G. M., ElSayed, N. A., Fadini, G. P., Galindo, R. J., Hirsch, I. B., Klonoff, D. C., McCoy, R. G., Misra, S., Gabbay, R. A., et al. (2024) · Diabetes Care · doi:10.2337/dci24-0032 · Cited by 278
Forlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
“30,31 Real-world studies of AID systems of various populations and use cases have reported anywhere from 60% to 82% TIR, and 1% to 3.6% time in hypoglycemia, 15–29 emphasizing the myriad of factors (country, age group, insurance status, device settings, bolus frequency, baseline glycemia, and more)…”
InfluentialSelf-citationThe role of automated insulin delivery technology in diabetes
Boughton, C. K., & Hovorka, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06165-w · Cited by 57
De Meulemeester, J., Keymeulen, B., De Block, C., Van Huffel, L., Taes, Y., Ballaux, D., Spincemaille, K., Lapauw, B., Vanhaverbeke, G., Lowyck, I., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06366-x · Cited by 27
Halperin, I. J., Wicklow, B., Amed, S., Chambers, A., Courage, C., Cummings, E., Kirkland, P., MacKay, D., Nakhla, M., Punthakee, Z., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.001 · Cited by 22
Metadata
- Authors
- Crabtree, T. S. J., Griffin, T. P., Yap, Y. W., Narendran, P., Gallen, G., Furlong, N., Cranston, I., Chakera, A., Philbey, C., Karamat, M. A., Saraf, S., Kamaruddin, S., Gurnell, E., Chapman, A., Hussain, S., Elliott, J., Leelarathna, L., Ryder, R. E. J., Hammond, P., Lumb, A., Choudhary, P., Wilmot, E. G., Contributors, T. A. C.-L. A., Evans, M., Gurnell, E., Hartnell, S., Davenport, K., O’Reilly, I., Brown, H., Kamaruddin, S., Pickering, S., Abouglia, K., Wadham, C., Rayman, G., Hussain, S., Brackenridge, A., Pender, S., Atkinson, R., Bahadur, M., Eid, H., Carling, J., Oldfield, L., Philbey, C., Hammond, P., Haywood, S., Gallen, G., Rodgers, H., Lovie, K., Whight, E., Nobel-Bell, G., Harris, S., Cartwright, A., Garnett, I., Harvey, J., McCulloch, F., Yap, Y. W., Weston, P., Chapman, A., Findlow, L., Leelarathna, L., Ohol, S., Thabit, H., Urwin, A., Cowlam, D., Thomas, S., Hyland, E., Yearsley, Z., Schofield, J., Soar, C., Fenn, L., Mendis, B., Htike, Z. Z., Cheyne, E., Emsley, J., Jones, E., Parfitt, V., Sawyer, L., Colosimo, S., Apsara, S., Mathara Diddhenipothage, D., Lumb, A., Hards, K., Edohen, F., Beaden, S., Cranston, I., Taylor, J., Skinner, L., Bawlchhim, Z., Tuthill, B., Cull, M. L., Ryder, R. E. J., Mitchell, S., Rimell, J., Foley, C., Gianfrancesco, C., Elliott, J., Butter, S., Carrieri, G., Douek, I., King, R., Lambert, P., Lionetti, P., Cardwell, J., Furlong, N., Keigan, S., Milne, R., Wilkinson, P., Ashton-Cleary, S., White, S., Anthony, K., Ribul Mazzola, S., Sweeney, S., Narendran, P., Karamat, A., Saraf, S., Hudson, B., Li, M., Skelding, R., Williams, L., Bartha, K., Jesson, A.-M., Grandy, L., Brewer, D., Edwards, J., Sears, N., Shergil, M., Baldwin, A., Crabtree, T., Van Heeswijk, I., Langeland, L., Taylor, N., Wilmot, E., Owen, S., Taylor, R., Robinson, E., Bakhit, M., Redfern, A., Kedge, C., Kotonya, C., Hayat, H., Gerrard, K., Pearson, N., Redfern, Z., Curtis, L., Galea, A., Weiss, M., Stacey, N., Partridge, H., Choudhary, P., Griffin, T., Ackroyd, D., Turrell, L., Chakera, A. J., Lambert, V., Suarez, A., Kirby, J., Lloyd, N., Karathenasi, E., McKinnon, S., Levitt, M., Govindan, R., Haskoll, B., Saunders, S., Kehinde, R., Lee, J., Galliford, T., Bickerton, A., Hammond, R., & Walker, R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-08-11
- Volume
- 46
- Issue
- 10
- Pages
- 1831-1838
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4385754731
- Cited by
- 88
- References
- 15
- FWCI
- 14.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study. https://app.cochat.ai/papers/10.2337/dc23-0635
- The paper
- Crabtree, T. S. J., Griffin, T. P., Yap, Y. W., Narendran, P., Gallen, G., Furlong, N., Cranston, I., Chakera, A., Philbey, C., Karamat, M. A., Saraf, S., Kamaruddin, S., Gurnell, E., Chapman, A., Hussain, S., Elliott, J., Leelarathna, L., Ryder, R. E. J., Hammond, P., . . . Walker, R. (2023). Hybrid Closed-Loop Therapy in Adults With Type 1 Diabetes and Above-Target HbA1c: A Real-world Observational Study. Diabetes Care. https://doi.org/10.2337/dc23-0635
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.